Company Description
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases.
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 27, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Dr. Jay S. Duker M.D. |
Contact Details
Address: 480 Pleasant Street, Suite B300 Watertown, Massachusetts 02472 United States | |
| Phone | 617-926-5000 |
| Website | eyepointpharma.com |
Stock Details
| Ticker Symbol | EYPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001314102 |
| CUSIP Number | 30233G209 |
| ISIN Number | US30233G2093 |
| Employer ID | 26-2774444 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay S. Duker M.D. | President, Chief Executive Officer and Director |
| Dr. John B. Landis M.S., Ph.D. | Interim Head of Research & Development and Director |
| Michael Pine | Chief Business Officer |
| George O. Elston | Executive Vice President and Chief Financial Officer |
| Michael J. Maciocio | Senior Vice President of Manufacturing and Operations |
| Ron I. Honig Esq. | Chief Legal Officer and Company Secretary |
| Jennifer Leonard | Chief People Officer and Senior Vice President of IT |
| David Scott Jones | Senior Vice President and Chief Commercial Officer |
| Isabelle Lefebvre | Chief Regulatory Officer |
| Dr. Marcia Sellos-Moura Ph.D. | Senior Vice President of Program Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 26, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| May 28, 2024 | 8-K | Current Report |
| May 14, 2024 | 144 | Filing |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| May 6, 2024 | 8-K | Current Report |
| May 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 30, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |